万维提示：
1、投稿方式：在线投稿。
2、期刊网址：http://www.uhod.org/
3、投稿网址：http://www.uhod.org/submit/
4、官网邮箱：uhod@uhod.org
5、官网电话：+90 312 305 2929
6、期刊刊期：季刊，一年出版4期。
2021年7月31日星期六
投稿须知【官网信息】
INSTRUCTIONS TO AUTHORS
1. Uluslararasi Hematoloji-Onkoloji Dergisi (UHOD) (International Journal of Hematology and Oncology) is a peer-reviewed and official journal of Akademi Doktorlar Yayinevi (Publisher) and publishes research articles, reviews, invited reviews, scientific meeting abstracts and letters to the editor in all aspects of both clinical and experimental Hematology, Oncology and Radiation Oncology.
2. UHOD is published every three months (one volume per annum).
3. The abbrevation of our journal for citing is “UHOD”.
4. It is the authority of Editorial Board to accept, reject or transmit the submitted manuscripts to Advisory Board for further review.
5. It is the author(s)’ responsibility that the submitted manuscript is original work, not previously published or is not being considered for publication elsewhere.
6. Statement of conflict of interests are required for each author. The authors should acknowledge and provide information on grants, contracts or other financial support of the study provided by any foundations and institutions or firms.
7. In the materials section of the manuscripts where experimental studies on humans are presented, a statement that informed consent were taken from the volunteers or patients after the explanation of the procedures should be included. This section also should contain a statement that the investigation confirms the principles outlined in Helsinki Declaration (available at www.ub.edu). For experimental studies on animals, research protocol should be in accordance with international agreements (Guide for the care and use of laboratory animals - www.grants.nih.gov). A copy of approval from ethics committee should be sent.
8. All manuscripts should be presented according to the following international guidelines. Randomized study – CONSORT, observational study – STROBE, study on diagnostic accuracy – STARD, systematic reviews and meta-analysis – PRISMA, animal experimental studies – ARRIVE, nonrandomized behavioral and public health intervention studies – TREND.
9. Manuscripts should be written in English.
10. Manuscripts should be sent by Online Submission system. Papers should be typed in 12 point typescript and double-spaced throughout the text including tables and references with wide margins (3 cm) on one side of a standard A4 paper.
11. Research papers, should not exceed 5000 words and include: Title page, English and Turkish abstracts, English and Turkish Keywords, Introduction, Materials (Patients) and Methods, Results, Discussion and References.
Title page: The title should be concise and reflect the purpose of the study. The title should be followed by the list of authors, including their full names with no academic degrees. Hospital or university affiliations should also be included. Correspondence address, phone and fax numbers and e-mail address should be written. Conflict of interest statement should be written on title page.
Abstract page: The abstract should be in English and Turkish with an appropriate titles, and should not exceed 250 words. It should start with a sentence indicating the rationale of the study and summarize the results and conclusions concisely. A list of up to 5 English and Turkish keywords should be included and should be consistent with the “Index Medicus” style (available at http://www.nlm.nih.gov).
Text pages: Background knowledge and the rationale of the study should be described in the “Introduction” with appropriate references. Clinical studies should be entitled “Patients and Methods” and, laboratory studies and animal experiments should be entitled “Materials and Methods”. “Results” should illustrate numerical data which should be supported with figures and tables. The data should be discussed in the light of recent literature in the “Discussion” that should not exceed half the length of whole article.
12. Short reports include the preliminary results, negative studies and other studies that are not to be published as a full text manuscript. Short reports should not exceed 2000 words and an abstract with no more than 50 words and 10 references.
13.Reviews written on timely and educational topics are accepted. Each review should normally be no longer than 5000 words with clear subheadings and 200 words in abstract. Reviews with no more than 3 authors are preferable.
14. Images in Hematology-Oncology section presents case reports with clinic, radiologic, and/or laboratory figures. It should not be more than 200 words with no more than 6 authors.
15. Letters to the editor concerning recent publications in the Journal, case reports and other subjects of particular interest are reviewed by the Editorial Board. They should be concise and limited to 1500 words with one figure or table and list up to 10 references.
16. Abbreviations should be standard. Any nonstandard abbreviations should be defined in the text when first used.
17. Tables and legends should be typed on separate pages at the end of the manuscript. Any explanation should be defined as a footnote, not in the legend line.
18. All illustrations, art works and figures should be original. It is the authors’ responsibility to obtain necessary permissions for any material with copyright. Illustrations, figures and graphics should be prepared in tiff format with a minimum resolution of 300 dpi. They should be clear, sharp, easily readable and legible. Illustrations must be cited in consecutive numerical order in the text. The staining method and the magnification rate should be indicated in microscopic illustrations (e.g.H&E, x400). Submitted photographs, figures and graphics should be of professional quality. Legends for the figures should be typed double-spaced on a separate page. They must be concise and represent summaries of findings. Authors should retain one copy of original art work.
19. References must be cited as numerals in superscript in the text and listed at the end of the paper in numerical order corresponding to the order of citation. Journal names should be abbreviated as listed in “Index Medicus”. Personal communications and unpublished data should be included within the text of the manuscript, not as references. List all authors up to four authors. For five or more authors, list the first three authors followed by “et al”. Note the following examples:
Journal articles:
Altundag O, Gullu I, Altundag K, et al. Induction chemotherapy with cisplatin and 5-fluorouracil followed by chemoradiotherapy or radiotherapy alone in the treatment of locoregionally advanced resectable cancers of the larynx and hypopharynx: results of single-center study of 45 patients. Head Neck 27: 15-21, 2005.
Journal Article in Press:
Cengiz M, Ozyigit G, Yazici G, et al. Salvage Reirradiaton with Stereotactic Body Radiotherapy for Locally Recurrent Head-and-Neck Tumors. Int J Radiat Oncol Biol Phys 2010 Jul 31. doi:10.1016/j.ijrobp.2010.04.027
Books:
Chao KSC, Ozyigit G. Intensity Modulated Radiation Therapy for Head&Neck Cancer. 1st edition. Philadelphia, Lippincott Williams&Wilkins, 2003: 34-36.
Book chapters:
Ozyigit G, Beyzadeoglu M, Ebruli C. Genitourinary system cancers. In: Basic Radiation Oncology. Beyzadeoglu M, Ozyigit G, Ebruli C (eds). 1st edition. Springer-Verlag Berlin, Heidelberg, 2010: 363-410.
Congress proceedings:
Appelbaum FR, Gilliland DG, Tallman MS. The biology and treatment of acute myeloid leukemia. In: 40th Annual Meeting of the American Society of Hematology Education Book. McArthur JR, Schechter GP, Schrier SL (eds). December 4-8, 1998, Miami Beach, Florida, 1998: 10-13.
Congress abstracts:
Ayhan A, Yasui W, Yokozaki H, Tahara E. Gastrointestinal karsinomlarda bcl-2 ekspresyonu ve gen degisiklikleri. XII. National Cancer Congress, Antalya, April 23-26, 1997: P307.
Thesis:
Güllü IH. Mide kanserli hastalarda 5-florourasil, adriamisin, mitomisin kombine kemoterapisinin degerlendirilmesi. Hacettepe University Faculty of Medicine, Oncology Institute, Medical Oncology Department Graduate Thesis, Ankara, 1992.
Internet resources:
http://www.cancer.gov/cancertopics/types/bladder (Access date: 12/14/208).
20. Copyright of the accepted papers published in the Uluslararasi Hematoloji-Onkoloji Dergisi (UHOD) belongs to Akademi Doktorlar Yayınevi (Publisher). The author(s) is (are) responsible for the scientific content of the manuscript.
21. "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" (Ann Intern Med 2004; 141: 477-478) should be referred to for further details of manuscript preparation (www.icmje.org).
